C2C Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

C2C Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$239K	Buy	+632	New	+$221K	0.19%	80
2026 Q2	–	Sell	-1,715	Closed	-$478K	–	96
2026 Q1	$478K	Hold	1,715	–	–	0.4%	47
2025 Q4	$520K	Hold	1,715	–	–	0.44%	46
2025 Q3	$481K	Hold	1,715	–	–	0.41%	47
2025 Q2	$414K	Hold	1,715	–	–	0.37%	52
2025 Q1	$418K	Hold	1,715	–	–	0.39%	52
2024 Q4	$563K	Sell	1,715 -10	-0.6%	-$3.39K	0.52%	42
2024 Q3	$618K	Hold	1,725	–	–	0.58%	42
2024 Q2	$471K	Hold	1,725	–	–	0.46%	45
2024 Q1	$597K	Hold	1,725	–	–	0.59%	40
2023 Q4	$560K	Hold	1,725	–	–	0.47%	51
2023 Q3	$606K	Hold	1,725	–	–	0.09%	120
2023 Q2	$674K	Hold	1,725	–	–	0.09%	121
2023 Q1	$824K	Hold	1,725	–	–	0.13%	97
2022 Q4	$780K	Hold	1,725	–	–	0.14%	73
2022 Q3	$775K	Hold	1,725	–	–	0.15%	74
2022 Q2	$845K	Hold	1,725	–	–	0.15%	74
2022 Q1	$957K	Hold	1,725	–	–	0.16%	77
2021 Q4	$1.3M	Buy	+1,725	New	+$1.29M	0.19%	68

Other funds holding BIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

Focused Alpha LLC Denver, Colorado $402M AUM 23.92% 1-Year Est. Return

C2C Wealth Management's BIO Position: Q3 2026 in Review

C2C Wealth Management opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 632 shares worth $239K. The stake represents 0.19% of the portfolio and ranks #80 among its holdings. This is a return to the name: C2C Wealth Management previously reported a position in BIO as recently as Q1 2026.

C2C Wealth Management first reported a position in BIO in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.3M in Q4 2021. 69 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

C2C Wealth Management held 632 shares of Bio-Rad Laboratories Class A worth $239K as of Q3 2026.
Bio-Rad Laboratories Class A was a new C2C Wealth Management position in Q3 2026.
Bio-Rad Laboratories Class A made up 0.19% of C2C Wealth Management's portfolio in Q3 2026, its #80 holding.
C2C Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and has held it in 19 quarters since.
C2C Wealth Management's Bio-Rad Laboratories Class A position peaked at $1.3M in Q4 2021.
69 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on C2C Wealth Management's 13F filing for Q3 2026, filed 20 Oct 2026.